HAIKOU,
China, Aug. 9, 2023 /PRNewswire/ -- China Pharma
Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company"
or "We"), a specialty pharmaceutical company, today announced
that its wholly-owned subsidiary Hainan Helpson Medical &
Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has
received the "Drug Supplementary Application Approval Notice" for
its candesartan tablets by National Medical Products Administration
of China (hereinafter referred to
as NMPA"), indicating that the Company's candesartan tablets have
passed the quality and efficacy consistency evaluation of generic
drugs.
The consistency evaluation of generic drugs evaluates approved
generic drugs based on the principle that generic drugs need to
reach the same level of quality and efficacy as the innovator drug,
and can replace the innovator drug in clinical practice. This not
only saves medical expenses, but also ensures the safety and
effectiveness of public medication.
Candesartan is an angiotensin II antagonist (ARB), suitable for
primary hypertension, and is the smallest dose of sartan drugs. The
dosage is 4-16mg, once a day. It is the most stable and strongest
receptor binding sartan drug. It is tightly bound to four sites of
AT1 receptor, with high affinity and slow dissociation
characteristics. It is used to maintain stable blood pressure
control for 24 hours; reduce the risk of morning spikes caused by
blood pressure fluctuations; reduce target organ damage caused by
blood pressure fluctuations; help to reduce the hospitalization
risk and mortality rate of patients with chronic heart failure, and
improve symptoms and exercise ability.
According to the 2023 edition of the China Cardiovascular
Disease Report compiled by the National Center for Cardiovascular
Disease in China, there are
currently 290 million cardiovascular disease patients in
China, including 270 million
hypertensive patients. According to data from Mi Nei Net, the sales of candesartan tablets in
urban, county-level public hospitals, and urban retail pharmacies
in China in 2021 were RMB226 million (USD$35
million) and RMB173 million
(USD$27 million), respectively.
Ms. Zhilin Li, China Pharma's
Chairman and CEO, commented, "Candesartan tablets have long been
one of our flagship products. We are excited that it passed
generic-drug-consistency-evaluation. Such achievement not only
shows that the quality and efficacy of our Candesartan have been
recognized by the NMPA, indicating its ability to replace the
innovator drug in clinical practice, but also signifies that it has
the qualification to participate in China's national centralized procurement,
which will greatly enhance our competitiveness in the field of
government procurement."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical
company that develops, manufactures and markets a diversified
portfolio of products, focusing on conditions with high incidence
and high mortality rates in China,
including cardiovascular, CNS, infectious, and digestive diseases.
The Company's cost-effective business model is driven by market
demand and supported by new GMP-certified product lines covering
the major dosage forms. In addition, the Company has a broad and
expanding nationwide distribution network across all major cities
and provinces in China. The
Company's wholly-owned subsidiary, Hainan Helpson Medical &
Biotechnology Co., Ltd., is located in Haikou City, Hainan
Province. For more information about China Pharma Holdings,
Inc., please visit www.chinapharmaholdings.com. The Company
routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
For more information, please contact Investor
Relations:
China Pharma Holdings, Inc.
Ms. Diana Na Huang
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
View original
content:https://www.prnewswire.com/news-releases/china-pharmas-candesartan-hypertension-product-passes-the-quality-and-efficacy-consistency-evaluation-of-generic-drugs-301896469.html
SOURCE China Pharma Holdings, Inc.